TrianglePT-112 (NCT05104736)
PT-112 trial for Thymic Epithelial Tumor (NCT05104736). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with progressive, unresectable thymoma or thymic carcinoma. Previous platinum chemotherapy is required unless standard cytotoxic chemotherapy was refused.
The idea: test PT-112, a metal-pyrophosphate compound intended to cause cancer-cell death that can activate an immune response. Infusions occur on days 1 and 15 of the first 28-day cycle, then day 1 of later cycles at a lower dose. Scans assess response every eight weeks. Biopsies are optional.
This phase 2 study plans 53 patients. Arun Rajan leads at NIH in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.